Search

Displaying results 2841 - 2850 of 10000 in total
  1. Drug

    Nedosiran

    go.drugbank.com/drugs/DB17635
    ApprovedInvestigational

    [A261685] Nedosiran was approved by the FDA on October 2<sup>nd</sup>, 2023, under the brand name RIVFLOZA to lower urinary oxalate levels in children 9 years of age and older and adults with primary … Nedosiran is an RNA interference targeting hepatic lactate dehydrogenase, the enzyme responsible for the conversion of glyoxylate to oxalate.

  2. Drug

    UCB7362

    go.drugbank.com/drugs/DB17096
    Experimental

    It has shown high potency in biochemical (IC<sub>50</sub> = 7 nM), _in vitro_ (_P. falciparum_ 3D7 lactate dehydrogenase growth inhibition assay IC<sub>50</sub> = 10 nM), and _in vivo_ (50 mg/kg dose … in mice) studies.

  3. Drug

    Medrogestone

    go.drugbank.com/drugs/DB09124
    ApprovedWithdrawn

    It was conceived as an alternative for an orally effective contraceptive option.[A31526] It was developed by Ayerst, approved in Canada in 1969 and its current status is cancelled post-marketing.

    Mixtures: PRESOMEN 28 COMP 0.3/5MG, PRESOMEN 28 COMP 0.3/5MGProducts: Colprone Tab 5mg
  4. Drug

    Icotrokinra

    go.drugbank.com/drugs/DB21724
    ApprovedInvestigational

    Icotrokinra is a first-in-class, targeted oral peptide and interleukin-23 (IL-23) receptor antagonist. … [L56108,L56118] Icotrokinra was approved by the US FDA in March 2026 for the systemic treatment of moderate-to-severe plaque psoriasis.[L56108]

  5. Target

    Vitamin K epoxide reductase complex subunit 1-like protein 1

    go.drugbank.com/bio_entities/BE0002329
    TargetHumans

    Involved in vitamin K metabolism. Can reduce inactive vitamin K 2,3-epoxide to active vitamin K, and may contribute to vitamin K-mediated protection against oxidative stress. Plays a role in vitamin K-dependent gamma-carboxylation of Glu...

    Polypeptides: Vitamin K epoxide reductase complex subunit 1-like protein 1
  6. Target

    Insulin-like growth factor-binding protein complex acid labile subunit

    go.drugbank.com/bio_entities/BE0009058
    TargetCarrierHumans

    Involved in protein-protein interactions that result in protein complexes, receptor-ligand binding or cell adhesion

    Polypeptides: Insulin-like growth factor-binding protein complex acid labile subunit
  7. Drug

    Landiolol

    go.drugbank.com/drugs/DB12212
    ApprovedInvestigational

    [A264733,A264738] First approved in Japan in 2002 [A264758] for the treatment of intraoperative tachyarrhythmias,[A264733] landiolol was approved in Canada in April 2024 [L51938] and in the US in November … [A264733] Compared to other beta-blockers, landiolol possesses unique pharmacodynamic and pharmacokinetic properties, in that it has a rapid onset and short duration of action, and has a greater affinity

  8. Drug

    MD-0727

    go.drugbank.com/drugs/DB05948
    Investigational

    MD-0727 is a novel, potent cholesterol absorption inhibitor (CAI) under investigation for the treatment of hypercholesterolemia (high cholesterol.

  9. Drug

    ALTU-135

    go.drugbank.com/drugs/DB05330
    Investigational

    This consistent and pure enzyme combination is designed to improve fat, protein and carbohydrate absorption in pancreatic insufficient individuals.

  10. Drug

    Lutropin alfa

    go.drugbank.com/drugs/DB00044
    ApprovedInvestigational

    In males, LH stimulates Leydig cell to produce testosterone. … Its pharmacological action mimics the biological activity of endogenous LH; an acute rise of LH, or LH surge, in females triggers ovulation and the development of the corpous luteum.